Why hasn't neuroprotection worked in Parkinson's disease?
Karl Kieburtz* and Bernard Ravina
Correspondence *University of Rochester Medical Center, 1351 Mount Hope Avenue, Suite 223, Rochester, NY 14620, USA
Email karl.kieburtz@ctcc.rochester.edu
Despite encouraging preclinical results, clinical trials of neuroprotective agents for Parkinson's disease have failed to show consistent clinical benefit. In this Viewpoint article, Karl Kieburtz and Bernard Ravina analyze the reasons behind this lack of success and draw conclusions on how to move forward.
Full text of this article is available with one of the following:
- Personal subscription Purchase your own personal subscription to this journal. Already a subscriber? Please log in for immediate access.
- 7 day single article pass for US$18 In order to purchase this article you must be a registered user. Please register or log in.
- Site licence Learn more about institutional site licences
Current Subscribers
Please log in to access the full text article using the login box at the top of the page.
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated.
NEWS AND VIEWS
L-DOPA, dyskinesia and striatal plasticityNature Neuroscience News and Views (01 May 2003)